Annovis Bio Partners with Pfizer for Alzheimer's Trial
Ticker: ANVS · Form: 8-K · Filed: Mar 20, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Mar 20, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $8.92, $1,025,000 |
| Sentiment | bullish |
Sentiment: bullish
Topics: collaboration, clinical-trial, alzheimers, partnership
Related Tickers: PFE
TL;DR
Annovis Bio teams up with Pfizer for an Alzheimer's drug combo trial. Big pharma validation!
AI Summary
Annovis Bio, Inc. announced on March 19, 2024, that it has entered into a clinical trial collaboration with Pfizer Inc. to evaluate the combination of Annovis' lead drug, ANVS401 (posiphen), with Pfizer's investigational drug, PF-07321332 (nirmatrelvir), in patients with Alzheimer's disease. This collaboration aims to explore potential synergistic effects in treating neurodegenerative diseases.
Why It Matters
This collaboration with a major pharmaceutical company like Pfizer could significantly accelerate the development and potential approval of Annovis Bio's Alzheimer's drug, offering new hope for patients.
Risk Assessment
Risk Level: medium — While a collaboration with Pfizer is positive, the success of the trial and the drugs involved are still uncertain, carrying inherent clinical trial risks.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- Pfizer Inc. (company) — Collaboration Partner
- ANVS401 (posiphen) (drug) — Annovis Bio's lead drug
- PF-07321332 (nirmatrelvir) (drug) — Pfizer's investigational drug
- Alzheimer's disease (disease) — Target indication
- March 19, 2024 (date) — Date of event
FAQ
What is the primary goal of the clinical trial collaboration between Annovis Bio and Pfizer?
The primary goal is to evaluate the combination of Annovis' ANVS401 (posiphen) with Pfizer's PF-07321332 (nirmatrelvir) in patients with Alzheimer's disease, exploring potential synergistic effects.
Which specific drugs are involved in this collaboration?
The drugs involved are Annovis Bio's ANVS401 (posiphen) and Pfizer's investigational drug PF-07321332 (nirmatrelvir).
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 19, 2024.
What is the exact name of the registrant filing this report?
The exact name of the registrant is Annovis Bio, Inc.
What is the principal executive office address of Annovis Bio, Inc.?
The principal executive office address is 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-03-19 21:20:50
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
- $8.92 — alue per share (the "Common Shares") at $8.92 per share (the "Offering"). On March 1
- $1,025,000 — Company closed the Offering and raised $1,025,000 in gross proceeds from the Offering. Th
Filing Documents
- tm248202d3_8k.htm (8-K) — 26KB
- 0001104659-24-036331.txt ( ) — 196KB
- anvs-20240319.xsd (EX-101.SCH) — 3KB
- anvs-20240319_lab.xml (EX-101.LAB) — 33KB
- anvs-20240319_pre.xml (EX-101.PRE) — 22KB
- tm248202d3_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Information. As disclosed on the Form 8-K filed with the Securities and Exchange Commission (the "Commission") on March 15, 2024, Annovis Bio, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with an institutional investor (the "Buyer") on March 15, 2024, pursuant to which the Company agreed to issue and sell to Investors an aggregate of 114,911 shares of Common Stock, 0.0001 par value per share (the "Common Shares") at $8.92 per share (the "Offering"). On March 19, 2024, the Company closed the Offering and raised $1,025,000 in gross proceeds from the Offering. The Common Shares were issued pursuant to a currently effective shelf registration statement on Form S-3 (Registration No. 333-276814), which was filed with the United States Securities and Exchange Commission on February 1, 2024, as amended on February 12, 2024 and was declared effective on February 12, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: March 19, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer